The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
The EFTISARC-NEO trial, with a data cut-off of 20 October 2024, also showed 71.4% of patients achieved a pathologic response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback